# SCIL-1Ra in COVID-19 Feasibility & PK/PD

> **NCT04462757** · PHASE2 · TERMINATED · sponsor: **University of Manchester** · enrollment: 5 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Anakinra 100Mg/0.67Ml Inj Syringe

## Key facts

- **NCT ID:** NCT04462757
- **Lead sponsor:** University of Manchester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-28
- **Primary completion:** 2020-08-31
- **Final completion:** 2020-12-23
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Lack of patients in the trial population from which to recruit and lack of funding
- **Last updated:** 2021-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04462757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04462757, "SCIL-1Ra in COVID-19 Feasibility & PK/PD". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT04462757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*